...
首页> 外文期刊>Archives of pharmacal research >Pharmacokinetics of verproside after intravenous and oral administration in rats.
【24h】

Pharmacokinetics of verproside after intravenous and oral administration in rats.

机译:静脉和口服给药后大鼠中维洛普生的药代动力学。

获取原文
获取原文并翻译 | 示例
           

摘要

Verproside, a catalpol derivative iridoid glucoside isolated from Pseudolysimachion longifolium, is a candidate for anti-asthmatic drug. The dose-dependency of the pharmacokinetics of verproside was evaluated in rats after intravenous and oral administration. After intravenous administration of verproside (2, 5 and 10 mg/kg doses), the systemic clearance (Cl) was significantly reduced and AUC was significantly increased at 10 mg/kg dose compared to 2 and 5 mg/kg doses. The volume of distribution at steady state (V (ss)) remained unchanged as the dose was increased. The extent of urinary excretion was low for both intravenous (3.3-6.2%) and oral (0.01-0.04%) doses. Isovanilloylcatalpol was identified as a metabolite after intravenous administration of verproside and showed the significant decreases in AUC and C (max) at 10 mg/kg verproside dose. The reduced systemic clearance of verproside at high doses appears to be due to the saturable metabolism. Upon oral administration of verproside (20, 50 and 100 mg/kg doses), C (max) was nonlinearly increased. The extent of verproside recovered from the gastrointestinal tract at 24 h after oral administration was 0.01-0.72% for all three doses studied. The absolute oral bioavailability (F) was 0.3 and 0.5% for 50 and 100 mg/kg doses, respectively. Low F appears to be due to first-pass metabolism.
机译:Verproside是从假拟伪长叶中分离出来的Catalpol衍生物虹彩样糖苷,是抗哮喘药的候选药物。在静脉和口服给药后,在大鼠中评估了维洛普生药代动力学的剂量依赖性。静脉给予Verproside(2、5和10 mg / kg剂量)后,与2和5 mg / kg剂量相比,全身清除率(Cl)显着降低,AUC显着增加。随着剂量的增加,稳态下的分布体积(V(ss))保持不变。静脉(3.3-6.2%)和口服(0.01-0.04%)剂量的尿排泄量均较低。静脉给予维普洛塞后,异vanilloylcatalpol被鉴定为代谢产物,在维普洛塞剂量为10 mg / kg时,AUC和C(最大值)显着降低。高剂量维洛生苷的全身清除率降低似乎是由于新陈代谢的饱和所致。口服Verproside(20、50和100 mg / kg剂量)后,C(最大值)呈非线性增加。对于所有三种剂量,口服给药后24小时从胃肠道中回收的Verproside含量均为0.01-0.72%。 50和100 mg / kg的绝对口服生物利用度(F)分别为0.3%和0.5%。低F似乎是由于首过代谢。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号